Zoledronic acid: a new advance in managing skeletal events in prostate cancer
- PMID: 12656892
- DOI: 10.1046/j.1464-410x.2003.04142.x
Zoledronic acid: a new advance in managing skeletal events in prostate cancer
Comment on
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458. J Natl Cancer Inst. 2002. PMID: 12359855 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical